Patent classifications
B01D15/32
Channeled fibers in separation of biologically active nanoparticles
A relatively fast, inexpensive, and non-destructive method for separation and isolation of biologically active nanoparticles is described. Methods include the use of solid phase separation medis such as channeled fibers in a hydrophobic interaction chromatography (HIC) protocol to isolate biologically active nanoparticles from other components of a mixture. Biologically active nanoparticles can include natural nanoparticles (e.g., exosomes, lysosomes, virus particles) as well as synthetic nanoparticles (liposomes, genetically modified virus particles, etc.)
METHODS FOR QUANTITATING INDIVIDUAL ANTIBODIES FROM A MIXTURE
The present disclosure relates to, inter alia, a method of quantitating an amount of an antibody molecule from a mixture comprising two or more antibody molecules, comprising separating each of the two or more antibody molecules from the mixture by hydrophobic interaction chromatography high performance liquid chromatography (HIC-HPLC) and quantitating an amount of each antibody molecule, wherein the molecular weight of each antibody molecule is within 15 kDa of any other antibody molecule in the mixture and either each antibody molecule is different from another antibody molecule in the mixture by more than about 0.25 unit on the Kyte & Doolittle hydropathy scale or each of the antibody molecules when run alone on HIC-HPLC elutes at distinct run time with little overlap from the other antibody molecules in the mixture, or both.
NON-PROTEIN A PURIFICATION METHOD FOR ADALIMUMAB
The present invention relates to a method of preparing a population of antibodies, whereby a desired high-purity and high-quality population of antibodies can be prepared by removing impurities without using an expensive protein A column, and in particular, production costs can be significantly reduced while achieving process automation; and a population of antibodies prepared thereby.
SYSTEMS AND METHODS FOR CHROMATOGRAPHY USE AND REGENERATION
Aspects of the present disclosure relate to a method of regenerating a hydrophobic interaction chromatography column to which a load mass has been applied, the method comprising passing one or more column volumes of an alkaline solution through hydrophobic interaction media within the column, wherein the alkaline solution exhibits a pH of between about 10 and about 14, and a conductivity of between 0.5 mS/cm and about 10 mS/cm, wherein material bound to the hydrophobic interaction media is removed. In some cases, the alkaline solution may include sodium hydroxide at a concentration of between, e.g., about 0.1 mM and 10 mM.
PSA-functionalized sol-gel sorbent materials and methods of preparation
The invention provides a sorbent material comprising a PSA that is synthesized via a sol-gel process. The sorbent material enables higher loading of PSA and other functional groups than conventional sorbents. The sorbent material can further encapsulate carbonaceous and/or non-carbonaceous particles that are distributed throughout the sorbent network. The invention also relates to a method of making the sorbent materials.
POLYPEPTIDE AFFINITY LIGANDS AND METHODS OF USING
The present invention relates to a novel polypeptide affinity ligand coupled to solid supports and affinity purification of IgG antibodies. The invention is comprised of (1) the design, generation, and purification of polypeptide ligands, (2) coupling of a polypeptide affinity ligand to a solid support matrix, (3) purification of IgG (polyclonal and monoclonal antibodies), and (4) cleaning and reuse of polypeptide supported solid matrix.
Inverse gas chromatography standard solutions, device and method
The invention relates to a standard solution for inverse gas chromatography and/or surface energy analysis; a volumetric container for preparing such a standard solution; a method of preparing such a standard solution for inverse gas chromatography and/or a surface energy analysis and a method of probing a solid sample. The standard solution comprises a series of three or more compounds of increasing carbon chain length of general formula (I): R—X wherein: for the three or more compounds R is a series of alkyl, a series of alkenyl or a series of alkynyl groups of increasing carbon chain length; and for all three or more compounds X is H, OH, CO.sub.2H, C(O)H, C(O)CH.sub.3, NH.sub.2, SH or halogen; and the relationship between carbon chain length and volume of the compounds of increasing carbon chain length of general formula (I) is determined by the following formula.
METHODS OF SEPARATING HOST CELL LIPASES FROM AN ANTI-LAG3 ANTIBODY PRODUCTION
Provided herein are methods of separating host cell lipases from an anti-LAG3 antibody or antigen binding fragment in chromatographic processes and methods of improving polysorbate-80 stability in an anti-LAG3 antibody formulation by separating host cell lipases from the anti-LAG3 antibody or antigen binding fragment using chromatographic processes. Also provided are pharmaceutical compositions comprising an anti-LAG3 antibody or antigen binding fragment and less than 2 ppm of a host cell lipase.
METHOD FOR EFFICIENTLY SEPARATING AND PURIFYING RECOMBINANT HUMAN COAGULATE FACTOR VIII FC FUSION PROTEIN
Disclosed is a method for efficiently separating and purifying recombinant human coagulate factor VIII Fc fusion protein. The method comprises steps of affinity chromatography and anion exchange chromatography; and the sample captured by means of the affinity chromatography is eluted with a salt ion buffer containing 5%-20% polyol organic solvents under the condition of pH 4.0 to 8.0, and the protein sample can be separated and purified to 85% or more by further ProteinA affinity chromatography. The purification method is simple to operate, naturally connects each step of chromatography, has a high recovery rate and low cost, and easily increases production.
MONOLITHIC BODY
The present invention relates to monolithic bodies, uses thereof and processes for the preparation thereof. Certain embodiments of the present invention relate to the use of a monolithic body in the preparation of a radioactive substance, for example a radiopharmaceutical, as part of a microfluidic flow system and a process for the preparation of such a monolithic body.